Coherus BioSciences Inc (NAS:CHRS)
$ 1.7421 -0.0179 (-1.02%) Market Cap: 199.86 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Robert W Baird Global Healthcare Conference Transcript

Sep 05, 2019 / 06:35PM GMT
Release Date Price: $21.05 (-3.31%)
Michael Eric Ulz
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst

Why don't we go ahead and get started here? So good afternoon and thanks for joining us. I'm Mike Ulz, one of the biotech analysts here at Baird. It's my pleasure to introduce Denny Lanfear, President and CEO of Coherus BioSciences, which is a company focused on biosimilars, currently in the early stages of their launch of UDENYCA.

So the format for today is a fireside chat. So please feel free to ask questions if you have them. But first, I'll turn it over to Denny just to give us a brief background on the company before we jump into Q&A.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you, Michael, and thank you all for joining us today. So we're very excited about 2019. I founded this company in 2010 with some former Amgen and Genentech colleagues, as you know. So this month, on September 20, we'll see the 9-year anniversary of the company's founding.

And I am personally highly gratified that we've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot